With regard to the role of mTOR inhibition in BRAF-mutant CRC cells, Mao et al. demonstrated that suppression of the AKT-mTOR signaling pathway enhances the sensitivity to BRAF inhibition in BRAF-mutant CRC cells [33]. This evidence concerns the gene AKT1 and colorectal carcinoma.